IDEXX Laboratories, Inc.

The Q1 2026 filing shows a business whose growth is concentrated in recurring revenue. Of the $142.4 million increase in total revenue, the largest share came from CAG, and within CAG, from consumables and reference laboratory services, which management ties to testing volumes across major regions. That is a useful pattern for a reader to examine, because recurring lines are usually less variable than instrument sales. CAG Diagnostics capital instruments also grew 32.7% to $42.4 million, which suggests placements feed future consumable demand. International CAG revenue grew 22.7% as reported but 13.4% organically, so currency explains a large part of that headline figure. The risk factors describe a company that depends on third parties for key inputs. Ortho-Clinical Diagnostics supplies Catalyst chemistry slides under agreements running to 2044, and IDEXX must buy its full requirements for that menu. Other sole-source items include ProCyte Dx analyzers, SediVue Dx instruments, and inVue Dx cytology consumables. Competition is named specifically: Mars brands Antech Diagnostics and Heska, Zoetis including Abaxis, and Covetrus in veterinary software, with Neogen and Thermo Fisher in water and livestock testing. Regulation also matters, since many livestock, poultry and rapid assay products need APHIS licensure before sale. The reported operating margin was 31.8% against 31.7% a year earlier, so profit grew roughly in line with revenue rather than faster. Readers may want to look at the MD&A segment income reconciliation and the risk factor sections on supplier concentration when assessing how durable these results are.

Catalyst.According to the 10-Q for the quarter ended March 31, 2026, revenue rose 14.3% to $1.14 billion from $998.4 million a year earlier. Organic growth was 11.2%, and currency added 3.1 points. Companion Animal Group (CAG) drove most of the increase, with revenue of $1.05 billion, up 14.6%. Management attributed the gain to higher volumes and realized prices in CAG Diagnostics recurring revenue, which rose 14.1% to $920.3 million. IDEXX VetLab consumables grew 19.7% to $412.6 million, and management cited a 12% increase in the installed base of premium instruments. Income from operations reached $362.6 million, up 14.5%, while gross margin widened to 63.4% from 62.4%.

Hidden risk.The 10-K risk factors show concentration in supply. Certain Catalyst chemistry slides are supplied by Ortho-Clinical Diagnostics under agreements set to expire in December 2044. IDEXX is obligated to purchase all of its requirements for its current Catalyst chemistry slide menu from Ortho, to the extent Ortho can supply them. Several other analyzers and consumables are sole or single-source, and some supply agreements carry minimum purchase obligations whose failure could cost IDEXX rights under those agreements. Growth is also helped by pricing, since management cites higher realized prices in several lines, and currency added 3.1 points to Q1 revenue growth. Operating expenses also rose, with general and administrative expense up 30.1% to $119.1 million, partly from a $5 million impairment of an equity investment.